KMT2A and acute myeloid leukemia: Another study, KOMET-001, is a phase 1/2 first-in-human trial investigating Ziftomenib, a KMT2A–menin inhibitor, in R/R AML; the cohort is composed of about 33% KMT2A-rearranged patients and 13% NPM1-mutated patients (the phase 2 portion is planned to assess NPM1-mutated AML) [132].